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INTRODUCTION
Tacrolimus (FK506) has emerged as a potent alternative
to cyclosporine for preventing acute graft-vs.-host disease
(GVHD) after matched unrelated donor (MUD) marrow
transplantation. In phase II studies, grades II–IV GVHD
occurred in 34–50% and grades III–IV GVHD in 12–25%
of MUD marrow transplant recipients receiving tacrolimus
in combination with minidose methotrexate [1,2] or with
standard dose methotrexate [3]. In these studies, a number
of toxicities related to tacrolimus were appreciated. Nephro-
toxicity was the most common problem. Serum creatinine
doubled from baseline in 63–88% of patients and exceeded
2 mg/dL in more than one-half of patients [1–3]. Other
complications included hypomagnesemia, hyperkalemia,
hypertension, and tremor. Hyperglycemia, headache,
seizures, and thrombotic thrombocytopenic purpura
occurred in a small number of patients. In solid organ trans-
plant recipients, such toxicities were related to elevated
whole-blood concentrations of tacrolimus [4].
The optimal dose schedule of tacrolimus for GVHD
prophylaxis is unknown. In a multicenter pilot study [5], the
initial dose of tacrolimus for MUD marrow transplant
patients was chosen empirically, and doses were modified
subsequently when toxicities were noted. Therapeutic drug
monitoring was used routinely, but the target range for
blood levels of tacrolimus was wide. The purpose of the cur-
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ABSTRACT
Tacrolimus has proved effective for preventing acute graft-vs.-host disease (GVHD) after unrelated donor marrow
transplantation, but the therapeutic window is apparently narrow. Therapeutic drug monitoring could potentially be
used to guide dose modifications, but the optimal target range of tacrolimus blood concentrations is unknown. We
determined whether acute GVHD and renal dysfunction correlated with tacrolimus whole blood levels as measured
by the IMx assay. Data were analyzed for 97 adults treated in a multicenter trial of tacrolimus and methotrexate or
methylprednisolone as GVHD prophylaxis after unrelated donor marrow transplantation. The rate of grades II–IV
GVHD was 49%; 81% of patients had a doubling of the serum creatinine; and 61% had a serum creatinine ,2
mg/dL. The initial tacrolimus target range for the clinical trial was 10–60 ng/mL. Tacrolimus blood levels were
averaged over a 14-day period, and Cox models were used with averaged blood levels as a time-dependent covariate.
No significant change was observed in the risks of acute GVHD, doubling of creatinine, need for dialysis, or death
over a tacrolimus blood level range of 5–40 ng/mL, but there was a direct correlation between risk of developing a
creatinine ,2 mg/dL and increasing tacrolimus blood levels (4.7% increased risk for each 1 ng/mL increase in blood
concentration, p , 0.001). When the tacrolimus level exceeded 20 ng/mL, there was a 2.2-fold increase in the rate
of renal toxicity (p , 0.001), a trend for an increase in mortality (relative risk 3.9, p 5 0.08), and no impact on the
risk of GVHD. This analysis supports 10–20 ng/mL as the therapeutic range of tacrolimus whole blood steady state
or trough levels for unrelated donor marrow transplantation.
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rent analysis was to determine whether there is a relation-
ship between tacrolimus whole blood levels and GVHD or
toxicity, and whether that relationship could be used to
guide dosing in MUD marrow transplant recipients.
PATIENTS AND METHODS
Patients
From May 1993 through October 1996, an open-label,
nonrandomized phase II study of three tacrolimus-based
regimens for prevention of acute GVHD after unrelated
donor marrow transplantation was conducted at four centers
[5]. Ninety-seven adults with hematologic malignancies
were treated. Patient and donor characteristics are listed in
Table 1. Eighteen percent of the patients had donors sero-
logically mismatched for human leukocyte antigen (HLA)
class I or class II, and the remainder of the patient–donor
pairs were at least serologically matched. Molecular class II
typing was not performed uniformly for this study. The pro-
tocol was approved by the institutional review board at each
institution, and written informed consent was obtained from
each patient.
GVHD prophylaxis
Tacrolimus was administered at 0.03 mg · kg21 · day21
(n581) or 0.04 mg · kg21 · day21 (n516) i.v. by continuous
infusion from Day 22. The higher dose was used at the
start of the study, and the protocol was subsequently revised
for use of the lower initial dose of tacrolimus when addi-
tional toxicity information became available. Following
engraftment and when able to take medications orally, the
patients received tacrolimus capsules at 2 times the daily i.v.
dose twice daily (conversion ratio 1 i.v.:4 p.o.). The dose was
tapered 33% at weeks 9 and 17, and tacrolimus was discon-
tinued on Day 180. Depending on the study site, patients
received the minidose methotrexate regimen (5 mg/m2 i.v.
on Days 1, 3, 6, and 11), the standard methotrexate regimen
(15 mg/m2 i.v. on Day 1 and 10 mg/m2 i.v. on Days 3, 6, and
11), or methylprednisolone (0.5 mg/kg twice daily on Days
1–14; Table 1).
Tacrolimus doses were adjusted to achieve a specific tar-
get whole-blood steady state or trough level (IMx assay,
Abbott Laboratories, Abbott Park, IL) [6] through the first 8
weeks posttransplant; the target range was 5–60 ng/mL at
the beginning of the study, and it was revised subsequently to
10–30 ng/mL. Whole blood concentrations were measured
daily weeks 1–3 posttransplant and at least twice weekly dur-
ing weeks 4–8. Blood samples were taken at steady state for
those on i.v. tacrolimus or at 12 hours after the last oral dose
(trough level). The dose of tacrolimus was reduced 25% for a
grade I toxicity, 50% for a grade II toxicity, and 75–100% for
any grade III or IV toxicity due to the study drug. For the
purposes of assessing nephrotoxicity, serum creatinine was up
to 1.5 times baseline for grade I, 1.5–3 times baseline for
grade II, and more than 3 times baseline for grade III.
Outcomes monitoring
Patients were observed prospectively for development
of toxicity or acute GVHD. Toxicity was graded according
to the criteria of the Southwest Oncology Group [7].
Serum creatinine was measured at least every other day
during weeks 1 and 2 posttransplant, twice weekly during
weeks 3 and 4, and weekly during weeks 5–8. The diagnosis
of GVHD was based on clinical evidence with histologic
confirmation, and GVHD was graded according to the
consensus criteria [8]. Patients were followed through 6
months posttransplant for adverse events, GVHD, relapse,
and survival. Clinical outcomes were described in detail
elsewhere [5]. Briefly, 49% of patients had grades II–IV
GVHD, 18% had grades III–IV GVHD, 81% had dou-
bling of the serum creatinine, 61% had a serum creatinine
.2 mg/dL, 20% required dialysis, and 54% survived
through Day 180.
Statistical considerations
At the time of analysis, minimum time from transplanta-
tion was 6 months. Risks of acute GVHD, doubling of
serum creatinine from baseline, occurrence of serum creati-
nine .2 mg/dL, dialysis, and mortality were calculated
according to the method of Kaplan and Meier. Correlations
between tacrolimus whole blood levels and outcomes were
assessed as described [4]. Briefly, whole blood tacrolimus
levels were averaged over the prior 14 days for each patient
each day, and the averaged level was used in the regression
models. Cox models were used with the averaged whole
blood level or with a dichotomous variable (averaged whole
blood level ,20 or >20 ng/mL) as a time-dependent
covariate to determine the relationship with clinical out-
comes. Patients were censored at the time of discontinua-
tion of tacrolimus, relapse, or death. Logistic regression was
used to obtain data for plots of incidence of acute GVHD or
nephrotoxicity by averaged tacrolimus whole blood level.
Similar results were obtained when levels were averaged
over a 7-day period.
Table 1. Patient and donor characteristics
Number of patients 97a
Median age 36 years
(range) (15–54)
Patient sex
Male 52 (54%)
Female 45 (46%)
Disease status
Early 50 (51%)
Advanced 47 (49%)
Preparative regimen
TBI-containing 77 (79%)
Chemotherapy only 20 (21%)
GVHD prophylaxis
Tacrolimus and standard MTX 44 (45%)
Tacrolimus and minidose MTX 37 (38%)
Tacrolimus and corticosteroid 16 (17%)
Median donor age 38 years
(range) (16–55)
Donor sex
Male 51 (53%)
Female 46 (47%)
Patient–donor pair sex-mismatched 42 (43%)
Patient–donor pair HLA-mismatched 17 (18%)
aNumber of patients (percentage of group) unless indicated otherwise.
TBI, total-body irradiation; MTX, methotrexate.
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RESULTS
Treatment compliance
All patients required dose reductions of tacrolimus.
Forty-two patients had discontinued use of tacrolimus dur-
ing i.v. or oral administration before Day 180. By Day 21,
the mean i.v. dose of tacrolimus was 0.024 mg · kg21 · day21
(80% of the initial i.v. dose), and by Day 100, the mean oral
dose was 0.089 mg · kg21 · day21 (3 times the inital i.v. dose).
Tacrolimus measurements
Tacrolimus whole blood levels rose rapidly during the
first 10 days of administration and declined thereafter as
doses were reduced for toxicities or as specified by the pro-
tocol taper design (Fig. 1). The highest individual
tacrolimus whole blood level was 60 ng/mL on Day 8 post-
transplant. Fifty patients (50%) developed a tacrolimus
whole blood level greater than 20 ng/mL during the study
period.
Correlation between tacrolimus level and outcome
Analysis of the hazard ratio of grades II–IV acute
GVHD by whole blood concentration of tacrolimus demon-
strated no significant difference in risk of GVHD over a
range of tacrolimus levels of 5–40 ng/mL (Fig. 2). By con-
trast, there was a significant increase in the risk of renal
insufficiency (serum creatinine .2 mg/dL) with increasing
tacrolimus whole blood levels (Fig. 2); the risk ratio was
1.047 (p , 0.001). The risk of renal insufficiency exceeded
that of GVHD at a tacrolimus whole blood level of ,16
ng/mL. With a tacrolimus level >20 ng/mL, the relative
risk of renal insufficiency was significantly increased and
there was a trend for greater mortality within the subse-
quent 2 weeks, but there was no correlation with GVHD or
need for dialysis (Table 2).
DISCUSSION
Although tacrolimus proved effective for preventing
acute GVHD in MUD marrow transplant recipients, the
toxicities encountered resulted in dose modifications for
many patients. Wide inter- and intra-individual variations in
absorption and clearance of tacrolimus [9] led to the interest
in therapeutic drug monitoring to guide dosing for individ-
ual patients, but the therapeutic dose range has not been
identified.
In this study, we report that within the tacrolimus whole
blood concentration range of 5–40 ng/mL, there was no
significant change in the risk of acute GVHD, demonstrat-
ing that tacrolimus is effective over a wide range of levels. A
similar result was reported for liver transplant recipients
[4,10]. The lower limit of the therapeutic range was not
established by our analysis. Tacrolimus levels just below our
proposed lower limit (10 ng/mL) may be still be adequate
for prevention of GVHD [1], but there are too few patients
with low tacrolimus levels in the current analysis to confirm
this. McMaster et al. [11] reported that some liver transplant
recipients with tacrolimus levels persistently below 5 ng/mL
have no signs of rejection. That is not to suggest, however,
that such a practice is acceptable in the absence of data
obtained with a more sensitive assay.
By contrast, we found a significant correlation between
nephrotoxicity and tacrolimus whole blood concentrations.
By the Cox regression analysis, there is a 4.7% increase in
the risk of developing a serum creatinine .2 mg/dL for
each 1 ng/mL increase in tacrolimus level. A similar correla-
Figure 1. Mean daily tacrolimus whole blood levels
Figure 2. Incidence of grades II–IV acute GVHD ( ) or serum
creatinine .2 mg/dL ( ) by the averaged tacrolimus whole
blood level indicated
Table 2. Analysis of the effect of tacrolimus whole blood level $20 ng/mL on
acute graft-vs.-host disease and renal dysfunction or death
Outcome Relative risk 95% CI p
Grades II–IV acute GVHD 0.97 0.48–1.98 0.94
Serum creatinine . twice 1.36 0.86–2.15 0.19
baseline
Serum creatinine . 2 mg/dL 2.22 1.30–3.80 ,0.001
Dialysis 1.47 0.42–5.08 0.55
Overall mortality 3.95 0.85–18.33 0.08
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tion was noted for liver and kidney transplant recipients
[4,10,12]. In our patients, the risk of nephrotoxicity was
,50% when the tacrolimus level was .20 ng/mL, and the
relative risk of a serum creatinine .2 mg/dL was increased
2.2-fold when the tacrolimus level was .20 ng/mL. More-
over, there was a trend for increased mortality with very
high tacrolimus levels as well. These parameters would,
therefore, define the upper limit of the therapeutic range.
By our analysis, 10–20 ng/mL is the therapeutic range
of tacrolimus whole blood steady state or trough levels for
MUD marrow transplant recipients. Because there is no
relationship between tacrolimus blood levels and risk of
GVHD, maintenance of lower blood levels (5–15 ng/mL)
may reduce the risk of complications without compromising
efficacy [1]. It should be noted that this recommendation
applies only when tacrolimus is measured by the whole
blood assay as described, because there is no correlation
between tacrolimus whole blood concentration and plasma
concentration measured by other methods [13].
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Q1 <<AU: Please indicate correct superscript affiliation of each co-author.>
Q2 <<AU: Please explain IMx assay.>
Q3 <<AU: Table 1: Please spell out/define TBI, MTX>.
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